Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathogen reduction: a precautionary principle paradigm.

Harvey J Alter1

  • 1Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA. halter@dtm.cc.nih.gov

Transfusion Medicine Reviews
|March 21, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Projected health benefits and cost offsets from the United States National Hepatitis C Elimination Initiative.

Nature communications·2026
Same author

Role of viral and host factors in determining the outcome of HBV-associated acute liver failure.

Journal of translational medicine·2026
Same author

Molecular and serologic analysis of linked blood donor and recipient samples to rule out transfusion-transmitted parvovirus B19 infection.

Frontiers in public health·2026
Same author

Hepatitis virus-associated B cell non-Hodgkin's lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription.

Scientific reports·2026
Same author

Antibody responses to a highly conserved peptide in HCV E2 protein correlate with chronicity or spontaneous clearance of HCV infection.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Selection and characterization of a broadly neutralizing class of HCV anti-E2 VH1-69 antibodies.

PLoS pathogens·2025
Same journal

Assessment of CTLA-4, LAG-3, and TIM-3 Expression in Pediatric Patients With β-Thalassemia Major and Their Association With Alloimmunization.

Transfusion medicine reviews·2026
Same journal

A Reply to "Beyond Implementation: The Need for Validation, Equity, and Real-World Accountability in AI for Transfusion Medicine".

Transfusion medicine reviews·2026
Same journal

Beyond Implementation: The Need for Validation, Equity, and Real-World Accountability in AI for Transfusion Medicine.

Transfusion medicine reviews·2026
Same journal

Trust Over Knowledge: Rethinking Donor Iron Supplementation Strategies in Modern Blood Services-Authors' reply.

Transfusion medicine reviews·2026
Same journal

The Effect of Stress Ball and Music on Anxiety, Distress, and Pain Levels During Platelet Apheresis Donation: Randomized Controlled Trial.

Transfusion medicine reviews·2026
Same journal

Therapeutic Plateletpheresis for Thrombocytosis: Critical Analytic Reviews and Original Multicenter Experience.

Transfusion medicine reviews·2026
See all related articles

Implementing preemptive pathogen reduction (PR) is crucial for preventing transfusion-transmitted infections. This proactive approach, unlike current reactive methods, can significantly reduce risks from viruses and bacteria in blood products.

Area of Science:

  • Transfusion Medicine
  • Infectious Disease Prevention
  • Biotechnology

Background:

  • Significant delays exist between recognizing transfusion-transmitted disease risks and implementing preventive strategies.
  • Reactive approaches to transfusion safety allow infections to occur due to inevitable delays.
  • Emerging and re-emerging transfusion-transmitted infections necessitate a new proactive paradigm.

Purpose of the Study:

  • To advocate for the adoption of preemptive pathogen reduction (PR) systems in blood transfusion safety.
  • To highlight the limitations of current reactive strategies in preventing transfusion-transmitted infections.
  • To propose a future direction for pathogen reduction technologies in blood products.

Main Methods:

  • Review of historical intervals between risk recognition and prevention for transfusion-transmitted diseases.

Related Experiment Videos

  • Evaluation of existing pathogen reduction (PR) systems (psoralen/UV-A, riboflavin/UV-A) for efficacy and safety.
  • Discussion of the potential application of PR technology to various blood components (platelets, plasma, red cells).

    • Main Results:

    • Pathogen reduction (PR) systems show efficacy and safety for platelets and plasma.
    • Psoralen/UV-A technology is already implemented for platelet PR in Europe.
    • PR can mitigate risks from nucleic acid-containing agents, including bacteria, but not prions.

    Conclusions:

    • Pathogen reduction (PR) offers a preemptive strategy to combat transfusion-transmitted infections.
    • PR can be implemented for platelets and plasma immediately, with further development for red cells.
    • A collaborative commitment is required from regulatory bodies, industry, and research institutions to advance PR technology.